文献速递甲状腺疾病

促甲状腺激素抑制患者的处理策略

Approach to the Patient With a Suppressed TSH.
PubMed 文献 · J Clin Endocrinol Metab · 2023-01-01

亚临床甲状腺功能亢进症(SCH)定义为血清促甲状腺激素(TSH)低于参考范围(多数检测法<0.4 mU/L)而游离甲状腺素(FT4)和游离三碘甲状腺原氨酸(FT3)在参考范围内。评估包括重复甲状腺功能检查、病因探查及不良结局风险评估,管理可选观察、放射性碘消融、抗甲状腺药物、甲状腺手术或射频消融,需根据病因、患者因素及治疗风险获益个体化选择。

要点

  • SCH定义为TSH低于参考范围(多数检测法<0.4 mU/L)而FT4和FT3正常。
  • 持续SCH与心房颤动、心力衰竭、骨丢失和骨折等不良事件风险增加相关。
  • 管理选项包括观察、放射性碘消融、抗甲状腺药物、甲状腺手术或射频消融,需个体化选择。

核心结论

  • 持续SCH与心血管事件(如心房颤动和心力衰竭)、骨丢失和骨折以及部分研究中的认知下降风险增加相关,但显示治疗改善结局的前瞻性研究仍有限。
  • 治疗选择应基于疾病病因、患者因素以及每种治疗选项的风险和获益。

研究设计与样本

  • 原文未报告研究设计。

主要发现

  • SCH定义为血清TSH浓度低于参考范围(多数检测法<0.4 mU/L),FT4和FT3在参考范围内。
  • 许多SCH患者临床甲状腺功能正常,而其他患者可能出现甲状腺激素过量的表现,如心动过速、震颤、不耐热、骨密度丢失或体重减轻。
  • 持续SCH与心房颤动、心力衰竭、骨丢失和骨折以及部分研究中的认知下降风险增加相关。
  • 显示治疗改善结局的前瞻性研究仍有限。

关键数值与推荐

  • SCH的实验室诊断标准为血清TSH浓度低于参考范围(多数检测法<0.4 mU/L),FT4和FT3在参考范围内。
  • 评估应包括重复甲状腺功能检查以确认持续TSH抑制、探查潜在病因以及评估TSH低于正常时患者不良结局的风险。
  • 管理选项包括无积极治疗的观察、甲状腺放射性碘消融、抗甲状腺药物、甲状腺手术或射频消融,视患者和临床情况而定。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 显示治疗改善结局的前瞻性研究仍有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Subclinical hyperthyroidism (SCH) is a laboratory diagnosis defined by a serum thyrotropin (TSH) concentration below the reference range (< 0.4 mU/L in most assays), and a free thyroxine (FT4) and 3,5,3'-triiodothyronine levels (FT3) in the reference range. Many patients diagnosed with SCH will be clinically euthyroid while others may present with manifestations characteristic of thyroid hormone excess, such as tachycardia, tremor, intolerance to heat, bone density loss, or weight loss. In addition to the laboratory abnormalities, patient factors such as age, symptoms, and underlying heart and bone disease are used to stratify patients for the risk of adverse outcomes and determine the appropriate treatment. Evaluation should include repeat thyroid function tests to document persistent TSH suppression, investigation of the underlying cause, as well as evaluation of the patient's risk of adverse outcomes in the setting of a subnormal TSH. Persistent SCH has been associated with an increased risk of a range of adverse events, including cardiovascular events such as atrial fibrillation and heart failure, bone loss and fracture, and in some studies, cognitive decline. Despite the consistent association of these adverse events with SCH, prospective studies showing improved outcomes with treatment remain limited. Management options include observation without active therapy, radioactive iodine ablation of the thyroid, antithyroid medication, thyroid surgery, or radiofrequency ablation, as appropriate for the patient and clinical setting. The choice of therapy should be guided by the underlying etiology of disease, patient factors, and the risks and benefits of each treatment option.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Praw SS, Brent GA. Approach to the Patient With a Suppressed TSH. J Clin Endocrinol Metab. 2023. PMID: 36329632. doi:10.1210/clinem/dgac635

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。